Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Alliance Pharma ( (GB:APH) ) just unveiled an announcement.
Alliance Pharma has announced a recommended acquisition by Aegros Bidco Limited, which will be implemented through a Court-sanctioned scheme of arrangement. The acquisition involves the entire issued share capital of Alliance and is supported by the Alliance Board, who recommend shareholders vote in favor of the scheme. An alternative offer is also available, though the Alliance Directors are unable to provide a recommendation on it. The acquisition is subject to shareholder approval and court sanction, with the scheme expected to become effective in the first half of 2025.
More about Alliance Pharma
Alliance Pharma is a company involved in the pharmaceutical industry, focusing on the development and marketing of pharmaceutical products. The company plays a significant role in the market, providing a range of healthcare solutions to meet diverse medical needs.
YTD Price Performance: 33.55%
Average Trading Volume: 3,215,536
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £330.3M
For a thorough assessment of APH stock, go to TipRanks’ Stock Analysis page.
